Virax Biolabs Appoints Iain Miller, PhD as Independent Director, Succeeding Yair Erez, to Propel Commercial Strategy

Reuters
07-29
<a href="https://laohu8.com/S/VRAX">Virax Biolabs</a> Appoints Iain Miller, PhD as Independent Director, Succeeding Yair Erez, to Propel Commercial <a href="https://laohu8.com/S/MSTR">Strategy</a>

Virax Biolabs Group Ltd. announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective July 29, 2025. Dr. Miller succeeds Yair Erez, who is stepping down from the Board. Dr. Miller brings extensive experience in diagnostics and MedTech sectors, having held senior roles at GE Healthcare, bioMérieux, and Massachusetts General Hospital. His expertise is expected to contribute to Virax's commercial strategy as the company expands its immune profiling platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA38859) on July 29, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10